HOME >> BIOLOGY >> NEWS
Clemson researcher receives Komen grant

rate.

Chen will use the Komen Foundation funding to further establish the molecular bases of the combination of PRL antagonist and Herceptin . "We hope that our research results will soon be translated into clinic and contribute to the battle against breast cancer," said Chen. More than 200,000 new U.S. breast cancer cases are diagnosed each year. Breast cancer is the most common form of cancer in women and can be diagnosed in men.

Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. If the spread is unabated, it can result in death. Cancer is caused by both external factors, such as radiation and chemicals, and internal factors, such as hormones, genetic mutations and immune conditions.


'"/>

Contact: Wen Y. Chen
wenc@clemson.edu
864-455-1457
Clemson University
28-May-2004


Page: 1 2

Related biology news :

1. Clemson University spin-off uses corn to make plastics, provide cleaner air
2. Clemson researcher places hope on pushy photons
3. Clemson University researcher reaches for the stars to prevent osteoporosis
4. Clemson launches S.C. DNA Learning Center
5. Clemson dedicates biotech research complex
6. Breakthrough Clemson research appears in Science
7. Clemson researcher takes part in breakthrough research on insects
8. Clemson researchers find bacteria fighter that does not promote bacterial resistance
9. Clemson researchers identify mental retardation gene
10. Clemson researchers create biosensors to protect nations food and water supplies
11. Clemson-led team makes breakthrough in controlling Bt resistance in pests

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clemson researcher receives Komen grant

(Date:6/17/2015)... Deutschland und GERMANTOWN, Maryland , June ... ®   Produktlinie mit DNA-Tests verbessert den ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) hat ... STR-Testkits der Produktlinie Investigator ® ... Markt eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke ...
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces that its leading payment security technology, the ... Experience! @ NYC June 18th. Digital Experience! @ ... in technology to over 300 of the top media covering ... Pavilion in New York City from ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company ... Philadelphia, PA. , The presentation took place on Tuesday, June 16 and ... the development of APX3330 for the treatment of pancreatic cancer. A copy of ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty from ... first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members ... course combines students from both universities and is taught on both continents. , ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
Cached News: